Human papillomavirus laboratory findings

Revision as of 15:43, 10 December 2012 by Maheep Sangha (talk | contribs) (Created page with "__NOTOC__ {{Human papillomavirus}} {{CMG}} ==Overview== == Pap Smear == {{main|Pap smear}} [[Image:ThinPrep Pap smear HPV.jpeg|thumb|left|350px|ThinPrep Pap smear with grou...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Sexually transmitted diseases Main Page

Human papillomavirus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Human papillomavirus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Human papillomavirus laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Human papillomavirus laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Human papillomavirus laboratory findings

CDC on Human papillomavirus laboratory findings

Human papillomavirus laboratory findings in the news

Blogs on Human papillomavirus laboratory findings

Directions to Hospitals Treating Human papillomavirus

Risk calculators and risk factors for Human papillomavirus laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]

Overview

Pap Smear

ThinPrep Pap smear with group of normal cervical cells on left and HPV-infected cells on right. The HPV-infected cells show features typical of koilocytes: enlarged (x2 or x3) nuclei and hyperchromasia.


Certain types of sexually transmitted HPVs can cause cervical cancer. Persistent infection with one or more of about a dozen of these "high-risk" HPV types is an important factor in nearly all cases of cervical cancer. The development of HPV-induced cervical cancer is a slow process that generally takes many years. During this development phase, pre-cancerous cells can be detected by annual or semi-annual cervical cytology Papanicolaou screening, colloquially known as "Pap" smear testing. The Pap test is an effective strategy for reducing the risk of invasive cervical cancer. The Pap test involves taking cells from the cervix and putting them on a small glass slide and examining them under a microscope to look for abnormal cells. This method is 70% to 80% effective in detecting HPV-caused cellular abnormalities. A more sensitive method is a “Thin Prep,” in which the cells from the cervix are placed in a liquid solution. This test is 85% to 95% effective in detecting HPV-caused cellular abnormalities. The last Pap test method is mainly used on women over 30. It is a combination Pap-HPV DNA test. If this test comes back negative women can usually wait 3 years before having the test done again. Detailed inspection of the cervix by colposcopy may be indicated if abnormal cells are detected by routine Pap smear. A frequently occurring example of an abnormal cell found in association with HPV is the koilocyte. (See figure.)

The Center for Disease Control (CDC) recommends that women get a Pap test no later than 3 years after their first sexual encounter and no later than 21 years of age. Women should have a Pap test every year until age 30. After age 30, women should discuss risk factors with their health care provider to determine whether a Pap test should be done yearly. If risk factors are low and previous Pap tests have been negative, most women only need to have tests every 2-3 years until 65 years of age (Centers for Disease Control 2005). Since these screening tools have been developed there has been a 70% decrease in cervical cancer deaths over the last 50 years. Pap smear testing has proven to be one of the most successful screening tests in the history of medicine, but the American College of Obstetricians and Gynecologists states the even the newer liquid based cytology methods (Thinprep and Surepath) may miss 15-35% of CIN3's and cancer.

A study published in April 2007 suggested the act of performing a Pap smear produces an inflammatory cytokine response, which may initiate immunologic clearance of HPV, therefore reducing the risk of cervical cancer. Women who had even a single Pap smear in their history had a lower incidence of cancer. "A statistically significant decline in the HPV positivity rate correlated with the lifetime number of Pap smears received."[1]

It has been suggested that Pap smear screening for anal cancer might be of benefit for some sub-populations of gay men.[2]

HPV Testing

An HPV test detects certain types of human papillomavirus (HPVs), depending on the test. A method for detecting the DNA of high-risk HPVs has recently been added to the range of clinical options for cervical cancer screening. In March 2003, the US FDA approved a "hybrid-capture" test, marketed by Digene, as a primary screening tool for detecting high-risk HPV infections that may lead to cervical cancer. This test was also approved for use as an adjunct to Pap testing, and may be ordered in response to abnormal Pap smear results.

Adding the HPV test for all women over thirty improves the sensitivity of the cytology test alone to nearly 100% and gives the clinician the option to extend the pap smear screening interval out to three years.

According to the CDC there is currently no test commercially available to determine infection in men. Genital warts are the only visible sign of HPV in men, and can be identified with a visual check of the genital area. These visible growths, however, are usually the result of non-carcinogenic HPV types. Vinegar solutions have been used to identify flat warts by making them more distinct, but most providers have found this technique helpful only in moist areas, such as the female genital tract.[3]

References

  1. [1], J Inflamm 2007;4.
  2. Chin-Hong PV, Vittinghoff E, Cranston RD; et al. (2005). "Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study". J. Natl. Cancer Inst. 97 (12): 896–905. doi:10.1093/jnci/dji163. PMID 15956651.
  3. http://www.cdc.gov/STD/HPV/STDFact-HPV-and-men.htm#test [January 2007]

Template:WH Template:WS